Literature DB >> 17541186

Discovery of novel 2-anilinopyrazolo[1,5-a]pyrimidine derivatives as c-Src kinase inhibitors for the treatment of acute ischemic stroke.

Harunobu Mukaiyama1, Toshihiro Nishimura, Hiroaki Shiohara, Satoko Kobayashi, Yoshimitsu Komatsu, Shinji Kikuchi, Eiichi Tsuji, Noboru Kamada, Hideki Ohnota, Hiroshi Kusama.   

Abstract

We synthesized a series of novel 2-anilinopyrazolo[1,5-a]pyrimidine derivatives and evaluated their ability to inhibit c-Src kinase; 7-(2-amino-2-methylpropylamino)-5-cyclopropyl-2-(3,5-dimethoxyphenylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide 7o and 7-(2-amino-2-methylpropylamino)-2-(3,5-dimethoxyphenylamino)-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide 7f showed potent inhibitory activity. Compound 7f inhibited c-Src selectively and exhibited satisfactory central nervous system (CNS) penetration. Furthermore, 7f.HCl reduced the infarct volume in vivo in a rat middle cerebral artery (MCA) occlusion model when administrated intraperitoneally.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17541186     DOI: 10.1248/cpb.55.881

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  2 in total

1.  Design, Synthesis and Antitumor Evaluation of Novel Pyrazolopyrimidines and Pyrazoloquinazolines.

Authors:  Mohamed El-Naggar; Ashraf S Hassan; Hanem M Awad; Mohamed F Mady
Journal:  Molecules       Date:  2018-05-23       Impact factor: 4.411

2.  miR-137 prevents inflammatory response, oxidative stress, neuronal injury and cognitive impairment via blockade of Src-mediated MAPK signaling pathway in ischemic stroke.

Authors:  Runhui Tian; Bo Wu; Cong Fu; Kaimin Guo
Journal:  Aging (Albany NY)       Date:  2020-06-04       Impact factor: 5.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.